IMUX

Immunic Inc

13.11

Sep 04 • 3:59 PM ET +0.35 (2.74%)

13.10

Aftermarket • 7:30 PM ET -0.01 (-0.07%)

Healthcare Biotechnology USA Micro NASD

Peers: AGEN CNTB GALT KZIA SPRO VRCA MOLN HURA ORMP PLX

| Held by: VTI VXF SURI SBIO AVSC QQQS

Scroll to Statements

Index	-
Market Cap	178.88M
Enterprise Value	24.35M
Income	-111.57M
Sales	0.00M
Book/sh	9.35
Cash/sh	11.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	92
IPO	Apr 17, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.40
P/C	1.15
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.05
Current Ratio	5.05
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.81
EPS next Y	-2.44
EPS next Q	-0.97
EPS this Y	41.91%
EPS next Y	32.26%
EPS next 5Y	25.58%
EPS past 3/5Y	45.16% 25.99%
Sales past 3/5Y	- -
EPS Y/Y TTM	50.66%
Sales Y/Y TTM	-
EPS Q/Q	60.47%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	31.32% -

Insider Own	6.53%
Insider Trans	0.00%
Inst Own	79.33%
Inst Trans	13.68%
ROA	-101.15%
ROE	-138.17%
ROIC	-87.22%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.88%
SMA50	-12.44%
SMA200	18.92%
Trades

Shs Outstand	13.64M
Shs Float	12.75M
Short Float	10.02%
Short Ratio	6.54
Short Interest	1.28M
52W High	17.43 -24.78%
52W Low	5.06 158.99%
Volatility	11.72% 8.04%
ATR (14)	1.16
RSI (14)	34.91
Beta	1.41
Rel Volume	2.16
Avg Volume	195.39K
Volume	421,300

Perf Week	-14.87%
Perf Month	-9.83%
Perf Quarter	2.66%
Perf Half Y	6.59%
Perf YTD	145.64%
Perf Year	70.26%
Perf 3Y	-23.78%
Perf 5Y	-87.02%
Perf 10Y	-99.47%
Recom	1.00
Target Price	43.09
Prev Close	12.76
Price	13.11
Change %	2.74%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-17-26	Initiated	Wedbush	Outperform	$45
May-22-26	Initiated	Wolfe Research	Outperform
Apr-17-26	Initiated	Stifel	Buy	$2.50
Apr-15-26	Downgrade	D. Boral Capital	Buy → Hold
Mar-24-26	Initiated	Guggenheim	Buy	$7
Nov-07-25	Initiated	Roth Capital	Buy	$3
Sep-29-25	Initiated	Chardan Capital Markets	Buy	$13
Mar-25-25	Initiated	William Blair	Outperform
Nov-25-24	Initiated	H.C. Wainwright	Buy	$10
Sep-09-24	Resumed	Leerink Partners	Outperform	$5
Aug-27-24	Initiated	B. Riley Securities	Buy	$6
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Sep-19-22	Resumed	H.C. Wainwright	Buy	$26
Apr-15-21	Initiated	Aegis Capital	Buy	$55
Mar-24-21	Initiated	JMP Securities	Mkt Outperform	$55
Oct-02-20	Initiated	SVB Leerink	Outperform	$45
Aug-26-20	Initiated	Piper Sandler	Overweight	$71
Aug-07-20	Resumed	ROTH Capital	Buy	$64
Jul-20-20	Initiated	BMO Capital Markets	Outperform	$40
Jun-05-20	Initiated	Wedbush	Outperform	$59

Show Previous Ratings

Sep-02-26 08:40AM	Immunic to host virtual relapsing MS R&D Day on September 9 (Proactive)
06:30AM	Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 (PR Newswire)
Sep-01-26 08:36AM	Immunic appoints Chitrang Davé as chief data and digital officer (Proactive) -7.72%
07:41AM	Nasdaq tumbles as rising yields fuel market selloff (Proactive)
06:30AM	Immunic Appoints Chitrang Dave as Chief Data and Digital Officer (PR Newswire)
08:36AM	Loading…
Aug-11-26 08:36AM	Immunic advances MS drug toward key Phase 3 data, expects results by year-end (Proactive) +9.79%
06:34AM	Immunic: Q2 Earnings Snapshot (Associated Press)
06:30AM	Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Aug-10-26 04:05PM	Immunic Appoints Elena Ridloff to Board of Directors (PR Newswire)
03:07PM	Immunic CEO on Q2 progress and Phase 3 MS trial milestones (Proactive)
Jul-09-26 06:30AM	Immunic to Participate in Investor Conferences in July (PR Newswire)
Jun-10-26 06:30AM	Immunic to Participate in Investor, Industry and Scientific Conferences in June (PR Newswire)
May-28-26 10:29AM	Immunic presents new vidofludimus calcium data at multiple sclerosis conference (Proactive) +6.93%
06:30AM	Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis (PR Newswire)
May-27-26 09:06AM	Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials (Proactive) +7.94%
06:30AM	Loading…
06:30AM	Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer (PR Newswire)
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
06:30AM	Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors (PR Newswire)
May-13-26 09:04AM	Immunic advances Phase 3 MS program, eyes topline data by year-end (Proactive) +8.82%
07:48AM	Nasdaq continues to gain but Dow still red as Trump arrives in China (Proactive)
06:35AM	Immunic: Q1 Earnings Snapshot (Associated Press)
06:30AM	Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
May-07-26 08:47AM	Immunic CEO on Q1 highlights, new appointments and upcoming milestones (Proactive) +6.62%
Apr-30-26 06:30AM	Immunic to Participate in Investor and Medical Conferences in May (PR Newswire)
Apr-28-26 08:40AM	Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout (Proactive) +7.72%
06:30AM	Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer (PR Newswire)
Apr-23-26 08:52AM	Immunic to implement 1-for-10 reverse stock split (Proactive)
08:00AM	Immunic, Inc. Announces 1-for-10 Reverse Stock Split (PR Newswire)
Apr-09-26 06:30AM	Immunic to Participate in Scientific and Medical Conferences in April (PR Newswire) +8.40%
Apr-07-26 08:05AM	Immunic COO highlights the importance of science-led innovation to mark World Health Day (Proactive)
06:30AM	Loading…
Apr-01-26 06:30AM	Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +7.77%
06:30AM	Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton (PR Newswire)
Mar-10-26 08:36AM	Immunic secures European patent for MS drug candidate vidofludimus calcium (Proactive)
06:30AM	Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium (PR Newswire)
Mar-03-26 07:08AM	Immunic to present at healthcare investor conferences in March (Proactive)
06:30AM	Immunic to Participate in Investor Conferences in March (PR Newswire)
Feb-28-26 03:00PM	Immunic secures $400M to support late-stage MS trials - ICYMI (Proactive)
Feb-26-26 09:02AM	Immunic sets stage for phase 3 MS data readout after $400M financing (Proactive)
07:08AM	Immunic: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update (PR Newswire)
Feb-17-26 04:33PM	Immunic closes $200M private placement to fund late-stage MS trials (Proactive)
04:05PM	Immunic Announces Closing of Oversubscribed Private Placement Financing (PR Newswire)
Feb-16-26 06:09AM	Immunic secures $400m fund to support commercial-stage development (Pharmaceutical Business Review)
Feb-14-26 08:15AM	Immunic MS trial shows reduced brain lesions - ICYMI (Proactive)
Feb-13-26 01:55PM	Why Is Immunic Stock Soaring Friday? (Benzinga)
11:25AM	Immunic Stock Jumps After Pricing $400 Million Private Placement (Benzinga)
11:20AM	Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push (Proactive)
09:03AM	Immunic to raise up to $400M to fund late-stage MS trials, commercial push (Proactive)
06:30AM	Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company (PR Newswire)
Feb-10-26 08:11AM	Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum (Proactive) +11.30%
Feb-04-26 08:45AM	Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS (Proactive) -5.43%
06:30AM	Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis (PR Newswire)
Jan-12-26 04:23AM	Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% (Insider Monkey)
Jan-07-26 06:30AM	Immunic Highlights 2025 Accomplishments and Upcoming Milestones (PR Newswire) +10.67%
Nov-26-25 06:30AM	Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December (PR Newswire)
Nov-13-25 06:39AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
06:30AM	Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 06:30AM	Immunic to Participate in Industry and Investor Conferences in November (PR Newswire) -5.01%
Oct-01-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in October (PR Newswire) +8.89%
Sep-25-25 06:30AM	Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Sep-09-25 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis (PR Newswire)
Sep-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in September (PR Newswire)
Aug-07-25 06:37AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) -7.87%
06:30AM	Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Jul-25-25 12:22PM	Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial (Insider Monkey)
Jun-24-25 06:30AM	Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis (PR Newswire)
Jun-05-25 06:30AM	Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS (PR Newswire)
Jun-03-25 04:01PM	Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) +6.11%
Jun-02-25 06:30AM	Immunic to Participate in Investor, Scientific and Industry Conferences in June (PR Newswire) +6.08%
May-29-25 07:05AM	Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering (PR Newswire) -25.28%
May-28-25 04:02PM	Immunic, Inc. Announces Proposed Public Offering (PR Newswire)
May-15-25 06:24PM	Immunic: Q1 Earnings Snapshot (Associated Press Finance)
May-02-25 06:30AM	Immunic to Participate in Scientific and Industry Conferences in May (PR Newswire)
May-01-25 01:56PM	Immunic presses ahead with MS drug despite Phase II endpoint miss (Clinical Trials Arena) +18.17%
Apr-30-25 07:30AM	Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial (PR Newswire) -22.65%
Apr-28-25 02:09AM	Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (Seeking Alpha)
Apr-10-25 01:00PM	Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-09-25 08:10AM	Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-01-25 06:30AM	Immunic, Inc. to Participate in Scientific and Industry Conferences in April (PR Newswire)
Mar-03-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in March (PR Newswire)
Feb-26-25 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Feb-20-25 07:30AM	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing (PR Newswire) +12.38%
Feb-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-07-25 06:30AM	Immunic Highlights 2024 Accomplishments and Upcoming Milestones (PR Newswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire) -9.29%
Nov-26-24 06:30AM	Immunic, Inc. to Participate in Investor Conference in December (PR Newswire)
Nov-14-24 06:35AM	Immunic announces publication of IMU-856 data (TipRanks) -6.84%
Nov-13-24 06:30AM	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (PR Newswire)
Nov-09-24 08:00AM	Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Nov-07-24 06:41AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (PR Newswire)
Oct-29-24 06:30AM	Immunic to Participate in Industry, Scientific and Investor Conferences in November (PR Newswire)
Oct-22-24 06:30AM	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (PR Newswire) -9.68%
Oct-09-24 05:31PM	Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... (GuruFocus.com) -6.67%
Sep-18-24 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (PR Newswire) +11.18%
Sep-04-24 06:30AM	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (PR Newswire)
Aug-28-24 06:30AM	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (PR Newswire)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

COO & PresidentMr. Jason Tardio M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMUX

Immunic Inc

Upgrade your Finviz experience